# Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes

## TL;DR

This study examines how often people without diabetes switch GLP-1 receptor agonists and how long they stick with the treatment.

## Contribution

The study provides new insights into treatment persistence and switching behaviors of GLP-1 receptor agonists in non-diabetic adults.

## Key findings

- Switching between GLP-1 receptor agonists is common within 12 months of treatment initiation.
- Treatment persistence rates vary significantly depending on the initial GLP-1 receptor agonist prescribed.

## Abstract

This cohort study evaluates glucagon-like peptide-1 (GLP-1) receptor agonist switching patterns and 12-month adherence and persistence among adults with overweight or obesity without diabetes.